BMY

百时美施贵宝
NYSE

实时行情|Nasdaq Last Sale

59.49
+1.24
+2.13%
盘后: 59.40 -0.09 -0.15% 19:38 09/25 EDT
开盘
58.26
昨收
58.25
最高
59.84
最低
58.16
成交量
983.59万
成交额
--
52周最高
68.34
52周最低
45.76
市值
1,340.87亿
市盈率(TTM)
-575.8955
分时
5日
1月
3月
1年
5年
新闻
财报
公告
公司事件
分析
简况
'Pandemic fatigue is hitting the nation': Expert
finviz · 3天前
Bristol Myers, Bluebird Bio Blood Cancer Treatment Gets FDA Priority Review; BLUE Stock Up
finviz · 3天前
FDA Accepts Application for Bristol-Myers Squibb and bluebird bio's Multiple Myeloma CAR-T Therapy
finviz · 4天前
U.S. Food and Drug Administration (FDA) Accepts for Priority Review Bristol Myers Squibb and bluebird bio Application for Anti-BCMA CAR T Cell Therapy Idecabtagene Vicleucel (Ide-cel, bb2121)
finviz · 4天前
欧狄沃辅助治疗食管癌及胃食管连接部癌术后患者可显著提高无病生存期
美通社 · 4天前
3 Dividend Stocks to Buy on Sale
finviz · 6天前
Bristol Myers' Opdivo with Exelixis drug cuts kidney cancer death risk -study
finviz · 09/18 22:05
Dr. Reddy's Settles Revlimid Patent Suit With Bristol Myers
finviz · 09/18 14:53
更多
财务预测
每股收益每股净资产每股现金流
实际值(美元)
预测值(美元)
利润表更多
净利润营业总收入营业利润
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流投资现金流筹资现金流
经营现金流(美元)
同比(%)
了解BMY最新的财务预测,通过BMY每股收益,每股净资产,每股现金流等数据分析百时美施贵宝近期的经营情况,然后做出明智的投资选择。
分析师评级

17位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测
分析师预测BMY价格均价为73.67,最高价位87.00,最低价为64.00。
EPS
机构持股
总机构数: 1,898
机构持股: 13.52亿
持股比例: 57.67%
总股本: 22.54亿
类型机构数股数
增持
704
1.44亿
建仓
123
1,031.75万
减持
691
8,265.68万
平仓
135
1,818.75万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
制药
+0.88%
制药与医学研究
+1.58%
高管信息
Chairman/Chief Executive Officer/Director
Giovanni Caforio
Chief Financial Officer/Executive Vice President
David Elkins
Chief Human Resource Officer/Senior Vice President
Ann Judge
Chief Human Resource Officer/Senior Vice President
Ann Powell
Executive Vice President/General Counsel
Sandra Leung
Executive Vice President/Director of Investor Relations
John Elicker
Executive Vice President
Nadim Ahmed
Executive Vice President
Christopher Boerner
Executive Vice President
Samit Hirawat
Executive Vice President
Kathryn Metcalfe
Executive Vice President
Elizabeth Mily
Executive Vice President
Louis Schmukler
Executive Vice President
Rupert Vessey
Senior Vice President/Chief Information Officer
Paul von Autenried
Senior Vice President/Chief Compliance Officer
Adam Dubow
Senior Vice President/Controller
Karen Santiago
Senior Vice President
Joseph Eid
Vice President/Director of Investor Relations/IR Contact Officer
Tim Power
Lead Director/Independent Director
Vicki Sato
Lead Director/Independent Director
vicki Sato
Independent Director
Peter Arduini
Independent Director
Robert Bertolini
Independent Director
Michael Bonney
Independent Director
Matthew Emmens
Independent Director
Julia Haller
Independent Director
Dinesh Paliwal
Independent Director
Paula Price
Independent Director
Derica Rice
Independent Director
Theodore Samuels
Independent Director
Gerald Storch
Independent Director
Karen Vousden
Independent Director
Phyllis Yale
  • 分红
  • 拆股
  • 内部人交易
公告日期
每股分红
除权日期
2020/09/10
Dividend USD 0.45
2020/10/01
2020/06/11
Dividend USD 0.45
2020/07/02
2020/03/02
Dividend USD 0.45
2020/04/02
2019/12/05
Dividend USD 0.45
2020/01/02
2019/09/11
Dividend USD 0.41
2019/10/03
2019/06/13
Dividend USD 0.41
2019/07/03
2019/03/07
Dividend USD 0.41
2019/04/04
2018/12/06
Dividend USD 0.41
2019/01/03
2018/09/12
Dividend USD 0.4
2018/10/04
2018/06/14
Dividend USD 0.4
2018/07/05
2018/03/01
Dividend USD 0.4
2018/04/05
2017/12/07
Dividend USD 0.4
2018/01/04
2017/09/13
Dividend USD 0.39
2017/10/05
2017/06/14
Dividend USD 0.39
2017/07/05
2017/03/03
Dividend USD 0.39
2017/04/05
2016/12/09
Dividend USD 0.39
2017/01/04
2016/08/04
Dividend USD 0.38
2016/10/05
2016/06/13
Dividend USD 0.38
2016/06/29
2016/03/04
Dividend USD 0.38
2016/03/30
2015/12/10
Dividend USD 0.38
2015/12/30
2015/09/18
Dividend USD 0.37
2015/09/30
2015/06/19
Dividend USD 0.37
2015/07/01
2015/03/05
Dividend USD 0.37
2015/04/01
2014/12/10
Dividend USD 0.37
2014/12/30
2014/09/17
Dividend USD 0.36
2014/10/01
2014/06/18
Dividend USD 0.36
2014/07/01
2014/03/04
Dividend USD 0.36
2014/04/02
2013/12/19
Dividend USD 0.36
2013/12/31
2013/09/18
Dividend USD 0.35
2013/10/02
2013/06/20
Dividend USD 0.35
2013/07/02
注册即可获得3个月
免费美股Level2深度行情
(Nasdaq Totalview)
立即领取
BMY 简况
百时美施贵宝公司从事生物医药产品的探索、研发、授权、制造、推广、分销及销售业务。该公司的医药产品包括化学合成药物、小分子药物和经生物加工制成的生物制剂。小分子药物为口服药丸或药片。生物制剂为注射产品或输液产品。该公司的产品包括埃罗妥珠单抗、纳武单抗、达沙替尼、伊匹单抗、艾乐妥、阿巴西普、博路定、Hepatitis C Franchise、Reyataz Franchise和Sustiva Franchise。该公司提供不同类型的治疗用药,用于治疗人类免疫缺陷病毒(HIV)感染等病毒性疾病、肿瘤、免疫系统病和心血管疾病。其产品销往世界各地的批发商、零售药房、医院、政府机构和医学界。该公司的子公司是Celgene Corp。
展开
热门股票
代码
价格
涨跌幅

微牛提供Bristol-Myers Squibb Co(NYSE-BMY)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的BMY股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易BMY股票基本功能。